v3.25.2
Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Revenues $ 422     $ 619
Net loss (2,895) $ (2,420) (2,389) $ (1,076) (5,315) (3,465)
Other Operating Segment [Member]            
Segment Reporting Information [Line Items]            
Revenues 422     619
Other research and development expenses [1] 78   13   204 16
Non-program expenses [2] 998   1,105   2,104 1,992
Personnel compensation and related expenses, including share-based compensation 1,102   1,124   2,170 1,957
Other segment items [3] 217   (645)   (473) (2,045)
Net loss (2,895)   (2,389)   (5,315) (3,465)
Other Operating Segment [Member] | Clinical Trial Studies [Member]            
Segment Reporting Information [Line Items]            
Program expenses [1] 539   604   1,209 1,320
Other Operating Segment [Member] | Manufacturing Renovocath [Member]            
Segment Reporting Information [Line Items]            
Program expenses [1] $ 383   $ 188   $ 720 $ 225
[1] Includes external research expenses, clinical studies, manufacturing development and non-recurring engineering costs, professional and consulting, regulatory, and trade shows.
[2] Includes selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance expenses, travel, and other office expenses.
[3] Includes interest income and interest expense and gain recognized on the fair value of common stock warrant liability.